Cancer Research UK is launching its first major brand advertising campaign since overhauling its identity earlier this year, in a bid to step away from “too clinical” perception and make research relevant to supporters.
The “thought-provoking” ad campaign, which launches on Boxing Day (26 December), aims to encourage people to donate and support its work by making its research relevant to them.
The campaign positions research as the enemy of cancer and aims to inspire people that beating cancer is an achievable goal.The TV ad states that research has beat diseases such as polio, and will one day beat cancer.
It will tell real stories of cancer patients to show the progress of its research and offer proof that investing in researcher saves lives. Real life stories include that of BBC Newsreader Nicholas Owen who survived kidney cancer.
Cancer Research says it is taking a different direction with the “bold” campaign in a bid to challenge current perceptions about scientific research and present a warmer persona. When the charity unveiled its new-look brand identity earlier this year it said one reason behind the change in approach was that a lot of people believe the charity was “too clinical”.
Natasha Hill, director of brand and strategic marketing at Cancer Research UK says: “This has got to be our boldest and most exciting advertising campaign so far. We’re taking a new approach which we hope will help reignite support for the work we carry out. We’re making progress day by day, but we can’t sit back and relax. One day we will beat all cancers, and we’d like everyone to help us make it sooner.”
Two TV ads, one focussing on childhood leukaemia and the other more generally on cancer sufferers, were created by AMV BBDO.
Activity will include press, PR, social digital, outdoor radio and TV. It will run until February 2013.
In November the charity launched a direct response TV ad using the new branding to encourage supporters to donate £2 a month.
This report provides comprehensive information on the current therapeutic developmental pipeline of FORUM Pharmaceuticals Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
The report provides brief overview of FORUM Pharmaceuticals Inc. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of FORUM Pharmaceuticals Inc.’s human therapeutic division and enlists all their major and minor projects
Evaluate FORUM Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline
Identify new drug targets and therapeutic classes in the FORUM Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Develop strategic initiatives by understanding the focus areas of FORUM Pharmaceuticals Inc. and exploit collaboration and partnership opportunities
Plan mergers and acquisitions effectively by identifying the most promising pipeline of FORUM Pharmaceuticals Inc.
Explore the dormant and discontinued projects of FORUM Pharmaceuticals Inc. and identify potential opportunities in those areas
This report is intended to assist buyers of graphic design services. Graphic design service providers plan, design and manage visual communication materials, such as printed materials, packaging and corporate identification. Buyers most commonly use these materials for product promotion. This report does not cover printing services, industrial design services, website design services or advertising agency services. Additionally, while this report includes the creation of graphics for packaging, it does not cover the physical design of packaging, which is addressed in ProcurementIQ's Packaging Design Services report.
The report “Medication Management Market by Systems (CPOE, CDSS, Automated Dispensing, Assurance Systems), Services (Medication Analytics, POC Verification, ADE Surveillance), Mode of Delivery (On-Premises, Web-Based, Cloud-Based) - Global Forecast to 2019” analyzes and studies major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
Browse 109 market tables and 40 figures spread through 300 pages and in-depth TOC on "Medication Management Market by Systems (CPOE, CDSS, Automated Dispensing, Assurance Systems), Services (Medication Analytics, POC Verification, ADE Surveillance), Mode of Delivery (On-Premises, Web-Based, Cloud-Based) - Global Forecast to 2019"
Medication management systems ensure tracking and validation of the medication administered to patients at all points of care. These systems help healthcare organizations to minimize medical errors occurring in the healthcare environment. Owing to these benefits, the global medication management market has received a major boost over the past few years.
With a significant increase in the elderly population and growth in treatment of long-term care diseases, an increasing number of patients across the world are using daily medication prescriptions. This has increased the risks of medication errors in the healthcare environment. Medication errors are responsible for a large number of hospital readmissions which adds to overall cost of healthcare services, which increases the burden on healthcare systems. Currently, an increasing number of healthcare organizations and governments across the globe are considering medication management solutions as tools for minimizing their overall healthcare costs. This can be achieved by minimizing the hospital stay for patients, while delivering better quality of care at the same time.
The global medication management market is estimated to grow at a healthy double-digit growth rate in the coming years. This growth is largely driven by the growing adoption of medication management solutions by healthcare organizations in both developed and developing countries across the world. In addition, investments by emerging countries such as China and South Korea in the medication management sector, the rising need for better healthcare, and an increase in government initiatives globally will help propel the growth of this market. However, medication management systems are perceived to be capital intensive solutions, which demand significant investments from a healthcare organization for their successful implementation and utilization. Thus, high cost of software implementation and the expenses associated with its timely up gradation and maintenance may hinder the growth of the medication management market to a certain extent.
In this report, the global medication management market is segmented by systems/software, services, modes of delivery, end users, and geography. This report also covers main market drivers, restraints, opportunities, and threats in the medication management market. The global medication management systems market, estimated to be valued at $845.1 million in 2014, is poised to grow at a CAGR between 13% and 15% during the forecast period of 2014 to 2019.
North America is estimated to be the largest market, accounting for a share of more than 60% of the global medication management market in 2014, followed by Europe, Asia-Pacific (APAC), and the Rest of the World (RoW), respectively. Growth in the ageing population, increasing government funding, and healthcare reforms are the factors that have supported the growth of the North American medication management market.
The medication management market is a fragmented market with companies like CareFusion Corporation (U.S.), McKesson Corporation (U.S.), Allscripts Healthcare Solutions, Inc. (U.S.), Cerner Corporation (U.S.), and Siemens Healthcare (Germany) commanding a majority share of the market in 2013.
Shares of 1-800-Flowers.com Inc. fell 7.1% Wednesday morning after the company lowered some guidance for 2018 and reported a decline in revenue during its second quarter.
The company now expects full-year revenue -- excluding acquisitions, divestitures and other items -- between $1.13 billion and $1.15 billion, slightly lower than its prior estimate of $1.14 billion to $1.16 billion. It also lowered its fiscal 2018 adjusted Ebitda forecast to $82 million to $85 million, from $90 million to $93 million.
The company raised its guidance for fiscal 2018 earnings per share and expects it to be between 62 cents and 64 cents, up from its previous expectation of 46 cents to 48 cents.
The Carle Place, N.Y., firm said the guidance changes were because of the company's results so far, the new tax law and its expectation that adjusted revenue growth will be more than 5% for the rest of fiscal 2018.
Chief Executive Chris McCann said in prepared remarks that problems in its Cheryl's Cookies business in the later part of the holiday season offset "positive trends." The production and fulfillment operations for that division experienced a temporary disruption because of a new system installed the prior quarter, Mr. McCann said.
Net revenue fell 5.1% to $526.1 million in its latest quarter. On an adjusted basis, omitting Fannie May results, net revenue rose 2.4%. The company in May completed its sale of Fannie May to Ferrero International SA.
Second-quarter profit was $70.7 million, or $1.06 a share, compared with $62.9 million, or 93 cents a share, in the year-earlier period. The company reported an adjusted profit of $58.5 million, or 88 cents a share, meeting expectations from analysts polled by Thomson Reuters.
Chinese President Xi Jinping applauds after the parliament passed a constitutional amendment lifting presidential term limits on Sunday in Beijing.
BEIJING — Since China’s Communist Party unveiled plans to let Xi Jinping remain president indefinitely, delegates to the national legislature have gushingly likened him to a Buddhist saint or the world’s longest-serving monarch.
Their devotion translated into a near-unanimous vote on Sunday to scrap presidential term limits and approve other constitutional changes to entrench Xi and his Communist Party’s dominance over Chinese life.
The vote, a formality for a congress dominated by Xi’s ruling party, stripped away an institutional check against one-man rule installed after the 1976 death of Mao Zedong, whose autocratic rule was marked by policy disasters and bloody power struggles.
It brought presidential tenures in line with Xi’s other, more powerful, posts of party chief and military-commission chairman, which aren’t subject to formal term limits. Delegates and officials say “centralized, unified leadership” under Xi will allow continuity in decision-making to better steer China’s modernization. Others saw the change as setting China on a risky path. The revision “disrupts the key feature that the Chinese Communist Party, unlike most other communist parties, had been able to achieve: leadership succession,” said Daniel Leese, a professor at Germany’s University of Freiburg. “The risk of compiling all power in one hand will become visible most clearly in periods of crisis,” said Leese, who has studied the Mao personality cult.